Merck Lipfendra FDA

FDA approves first oral PCSK9 inhibitor for managing cholesterol

The FDA approved Merck’s Lipfendra, the first oral PCSK9 inhibitor for reducing LDL cholesterol. Analysts project annual sales exceeding $2 billion, marking a significant milestone for macrocyclic pep